EA200300379A1 - Селективные агонисты рецептора ep4 в лечении остеопороза - Google Patents

Селективные агонисты рецептора ep4 в лечении остеопороза

Info

Publication number
EA200300379A1
EA200300379A1 EA200300379A EA200300379A EA200300379A1 EA 200300379 A1 EA200300379 A1 EA 200300379A1 EA 200300379 A EA200300379 A EA 200300379A EA 200300379 A EA200300379 A EA 200300379A EA 200300379 A1 EA200300379 A1 EA 200300379A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bone
bone mass
receptor
relates
loss
Prior art date
Application number
EA200300379A
Other languages
English (en)
Inventor
Кимберли О'Киф Кэмерон
Брюс Аллен Лефкер
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200300379A1 publication Critical patent/EA200300379A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Данное изобретение касается селективных в отношении рецептора EP4 агонистов простагландина формулы (I), где R, X, Z и Q являются такими, как определено в описании. Данное изобретение также относится к фармацевтическим композициям, содержащим эти соединения. Данное изобретение также относится к способам лечения состояний, которые представлены низкой костной массой, в частности остеопороза, хрупкости костей, остеопорозного перелома, дефекта кости, детской идиопатической потери массы костей, потери массы альвеолярного отростка, потери массы нижнечелюстной кости, перелома кости, остеотомии, потери массы кости, связанной с периодонтитом, или врастания протеза у млекопитающего, при которых вводят эти соединения.Отчет о международном поиске был опубликован 2002.07.25.
EA200300379A 2000-11-27 2001-11-05 Селективные агонисты рецептора ep4 в лечении остеопороза EA200300379A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327500P 2000-11-27 2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en) 2000-11-27 2001-11-05 Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
EA200300379A1 true EA200300379A1 (ru) 2003-08-28

Family

ID=22959588

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300379A EA200300379A1 (ru) 2000-11-27 2001-11-05 Селективные агонисты рецептора ep4 в лечении остеопороза

Country Status (41)

Country Link
US (3) US6552067B2 (ru)
EP (1) EP1339678B1 (ru)
JP (2) JP3984164B2 (ru)
KR (1) KR20030053063A (ru)
CN (1) CN1476429A (ru)
AR (1) AR035074A1 (ru)
AT (1) ATE374182T1 (ru)
AU (1) AU2002210848A1 (ru)
BG (1) BG107697A (ru)
BR (1) BR0115687A (ru)
CA (1) CA2429850C (ru)
CY (1) CY1106976T1 (ru)
CZ (1) CZ20031257A3 (ru)
DE (1) DE60130675T2 (ru)
DK (1) DK1339678T3 (ru)
EA (1) EA200300379A1 (ru)
EC (1) ECSP034623A (ru)
EE (1) EE200300246A (ru)
ES (1) ES2291361T3 (ru)
GT (2) GT200100238A (ru)
HN (1) HN2001000266A (ru)
HU (1) HUP0400807A2 (ru)
IL (1) IL155368A0 (ru)
IS (1) IS6775A (ru)
MA (1) MA26961A1 (ru)
MX (1) MXPA03004623A (ru)
NO (1) NO20032360L (ru)
NZ (1) NZ525164A (ru)
OA (1) OA12533A (ru)
PA (1) PA8533901A1 (ru)
PE (1) PE20020637A1 (ru)
PL (1) PL362030A1 (ru)
PT (1) PT1339678E (ru)
SI (1) SI1339678T1 (ru)
SK (1) SK5562003A3 (ru)
SV (1) SV2003000746A (ru)
TN (1) TNSN01166A1 (ru)
TW (1) TW200424170A (ru)
UY (1) UY27038A1 (ru)
WO (1) WO2002042268A2 (ru)
ZA (1) ZA200302803B (ru)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339678B1 (en) * 2000-11-27 2007-09-26 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
DK1408961T3 (da) * 2001-07-16 2007-11-05 Hoffmann La Roche 2 pyrrolidon-derivater som prostanoide agonister
AU2002328855B2 (en) 2001-07-16 2005-11-24 F. Hoffmann-La Roche Ag Prostaglandin Analogues As EP4 Receptor Agonists
IL159996A0 (en) * 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
RU2306309C2 (ru) 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
JP2005526080A (ja) * 2002-03-18 2005-09-02 ファイザー・プロダクツ・インク 肝不全、動脈管閉鎖、緑内障又は高眼圧の治療のための選択的ｅｐ４受容体アゴニストの使用
ES2268327T3 (es) * 2002-03-18 2007-03-16 Pfizer Products Inc. Uso de un selectivo de un receptor de ep4 para el tratamiento de enfermedades.
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US20050239872A1 (en) * 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
EP1513523A1 (en) * 2002-06-06 2005-03-16 Merck Frosst Canada & Co. 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
JP4754820B2 (ja) * 2002-06-10 2011-08-24 メルク セローノ ソシエテ アノニム プロスタグランジン作動薬としてのγラクタムおよびその使用
GB0219143D0 (en) * 2002-08-16 2002-09-25 Univ Leicester Modified tailed oligonucleotides
HUE029417T2 (en) 2002-10-10 2017-02-28 Ono Pharmaceutical Co Microspheres containing ONO-1301
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
JP2006510742A (ja) 2002-11-08 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼科組成物
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
US7256211B1 (en) * 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
WO2004078103A2 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7465755B2 (en) 2003-07-18 2008-12-16 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1664011A4 (en) 2003-09-02 2009-02-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
WO2005025568A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CN102558231B (zh) 2003-09-04 2015-05-27 默沙东公司 用于治疗高眼压的眼用组合物
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005060946A1 (en) * 2003-12-17 2005-07-07 Pfizer Products Inc. Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7563816B2 (en) 2004-07-20 2009-07-21 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7858650B2 (en) 2004-10-22 2010-12-28 Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation
US20080132543A1 (en) * 2004-10-26 2008-06-05 Wha Bin Im Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
WO2006052893A2 (en) 2004-11-08 2006-05-18 Allergan, Inc. Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
KR100890490B1 (ko) * 2005-01-27 2009-03-26 아사히 가세이 파마 가부시키가이샤 헤테로 6원환 화합물 및 그의 용도
JP5254007B2 (ja) * 2005-05-06 2013-08-07 アラーガン インコーポレイテッド 置換β−ラクタム及び医薬におけるその使用
US7772392B2 (en) 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7893107B2 (en) 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) * 2006-02-15 2006-07-19 (주)아이앤씨 수직형 대형 폐기물 파쇄기
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
AU2007334038A1 (en) 2006-12-18 2008-06-26 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
JP5479092B2 (ja) 2007-05-08 2014-04-23 国立大学法人浜松医科大学 Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
ES2395875T3 (es) * 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US8063033B2 (en) * 2008-01-18 2011-11-22 Allergan, Inc. Therapeutic beta-lactams
US8202855B2 (en) 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams
US7705001B2 (en) * 2008-03-18 2010-04-27 Allergan, Inc Therapeutic substituted gamma lactams
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
EP2488168A1 (en) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Combination therapy treatment for viral infections
BR112012022632B1 (pt) * 2010-03-08 2020-03-31 Kaken Pharmaceutical Co., Ltd. Medicamento compreendendo Agonista de ep4
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) * 2010-06-16 2011-12-21 LEK Pharmaceuticals d.d. Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
EP2675491A2 (en) 2011-02-17 2013-12-25 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013105997A2 (en) 2011-02-23 2013-07-18 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
JP6141430B2 (ja) 2012-07-19 2017-06-07 ケイマン ケミカル カンパニー， インコーポレーテッド Ｅｐ４介在性骨関連疾患及び病態用ジフルオロラクタム組成物
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
WO2014144500A2 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
KR20150130326A (ko) * 2013-03-15 2015-11-23 카이맨 케미칼 컴파니 인코포레이티드 Ep4-매개 질환 및 병태의 치료에서 사용하기 위한 ep4 수용체 선택적 효현제로서 락탐 화합물
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
AU2015269064B2 (en) 2014-06-06 2020-02-13 Allergan, Inc. Novel EP4 agonists as therapeutic compounds
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
US10400000B2 (en) 2015-06-12 2019-09-03 Simon Fraser University Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
MX2020006307A (es) 2017-12-25 2020-09-17 Asahi Kasei Pharma Corp Compuesto ciclico de 6 miembros que contiene nitrogeno.
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1158163A (en) 1966-06-15 1969-07-16 Berk Ltd Improvements in or relating to Polymer Compositions
ZA72645B (en) * 1971-03-05 1972-11-29 Upjohn Co Prostaglandin analogs
DE2346706A1 (de) * 1973-09-17 1975-04-03 Hoechst Ag Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
NL7604330A (nl) 1975-04-28 1976-11-01 Syntex Inc Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4320136A (en) * 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (ru) 1992-03-05 1996-10-11 Pfizer
SE9302334D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
ZA944647B (en) 1993-07-06 1995-01-06 Astra Ab Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
US5955481A (en) 1994-03-28 1999-09-21 Nissan Chemical Industries, Ltd. Pyridine type thiazolidines
TW420669B (en) 1994-03-28 2001-02-01 Nissan Chemical Ind Ltd Pyridine type thiazolidines
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AP2001002357A0 (en) * 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
PT1132086E (pt) * 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
EP1339678B1 (en) * 2000-11-27 2007-09-26 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
BG107697A (en) 2004-01-30
PE20020637A1 (es) 2002-07-18
US20030149086A1 (en) 2003-08-07
ES2291361T3 (es) 2008-03-01
ZA200302803B (en) 2004-04-13
GT200100238A (es) 2002-06-26
US20040259921A1 (en) 2004-12-23
HUP0400807A2 (hu) 2004-07-28
CA2429850A1 (en) 2002-05-30
CA2429850C (en) 2008-12-30
JP3984164B2 (ja) 2007-10-03
CN1476429A (zh) 2004-02-18
ATE374182T1 (de) 2007-10-15
NO20032360L (no) 2003-07-23
UY27038A1 (es) 2002-07-31
NO20032360D0 (no) 2003-05-26
NZ525164A (en) 2005-04-29
AR035074A1 (es) 2004-04-14
HN2001000266A (es) 2002-01-30
MXPA03004623A (es) 2003-09-05
US6747054B2 (en) 2004-06-08
PT1339678E (pt) 2007-11-30
JP2004521869A (ja) 2004-07-22
PL362030A1 (en) 2004-10-18
TNSN01166A1 (fr) 2005-11-10
US7192979B2 (en) 2007-03-20
KR20030053063A (ko) 2003-06-27
DE60130675D1 (de) 2007-11-08
TW200424170A (en) 2004-11-16
WO2002042268A2 (en) 2002-05-30
SI1339678T1 (sl) 2007-12-31
CZ20031257A3 (cs) 2004-04-14
CY1106976T1 (el) 2012-09-26
WO2002042268A3 (en) 2002-07-25
ECSP034623A (es) 2003-07-25
IL155368A0 (en) 2003-11-23
IS6775A (is) 2003-04-10
SV2003000746A (es) 2003-01-13
US20020065308A1 (en) 2002-05-30
PA8533901A1 (es) 2002-11-28
GT200100238AA (es) 2004-05-12
EP1339678B1 (en) 2007-09-26
DE60130675T2 (de) 2008-01-24
JP2007197467A (ja) 2007-08-09
AU2002210848A1 (en) 2002-06-03
SK5562003A3 (en) 2004-08-03
OA12533A (en) 2006-06-05
EE200300246A (et) 2003-10-15
US6552067B2 (en) 2003-04-22
DK1339678T3 (da) 2008-02-04
MA26961A1 (fr) 2004-12-20
EP1339678A2 (en) 2003-09-03
BR0115687A (pt) 2003-09-09

Similar Documents

Publication Publication Date Title
EA200300379A1 (ru) Селективные агонисты рецептора ep4 в лечении остеопороза
EA200200505A1 (ru) Селективные агонисты рецептора ep4 при лечении остеопороза
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
DK1408961T3 (da) 2 pyrrolidon-derivater som prostanoide agonister
DK1436257T3 (da) Oxim-analogica af 1-alpha, 25-dihydroxy-vitamin-D3 med ringe kalcemisk virkning
CY1108012T1 (el) Εγχεομενες στερεες ραβδοι και παστες φωσφορικου ασβεστιου για απελευθερωση οστεογονικων πρωτεϊνων
AP9801269A0 (en) Prostaglandin agonists.
ES2311803T3 (es) Composiciones embolicas de silicie pirogena.
EA200401502A1 (ru) Инъецируемые твердые переносчики гиалуроновой кислоты для доставки остеогенных протеинов
BRPI0417621A (pt) terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
CA2334257A1 (en) Treatment of osteoporosis with ep2/ep4 receptor selective agonists
EA200200774A1 (ru) Новые соединения, обладающие гиполипидемической, гипохолестеринемической активностью, способ их получения и содержащие их композиции
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
AU2003251729A8 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp
EA200300556A1 (ru) Композиция n-(метилэтиламинокарбонил)-4-(3-метилфениламино)-3-пиридилсульфонамида и циклических олигосахаридов
CR6952A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
DE69916932T2 (de) Kombinationstherapeutika, enthaltend einen selektiven Östrogenrezeptormodulator und Prostaglandin E2